Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review

Volume: 62, Pages: 61 - 73
Published: Jan 1, 2018
Abstract
Purpose Despite advances in the treatment of colorectal cancer, third-line treatment options are still limited. Regorafenib was approved in 2012 for the treatment of patients with metastatic colorectal cancer previously treated with approved standard therapy. The purpose of this review is to present existing clinical data on regorafenib. Method We systematically searched the PubMed and Embase databases, as well as ASCO and ESMO conference...
Paper Details
Title
Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review
Published Date
Jan 1, 2018
Volume
62
Pages
61 - 73
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.